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Abstract: Growth factors and other agents that could potentially enhance tissue regeneration 
have been identified, but their therapeutic value in clinical medicine has been limited for 
reasons such as difficulty to maintain bioactivity of locally applied therapeutics in the 
protease-rich environment of regenerating tissues. Although human diseases are treated with 
systemically administered drugs in general, all current efforts aimed at enhancing tissue 
repair with biological drugs have been based on their local application. The systemic 
administration of growth factors has been ruled out due to concerns about their safety. These 
concerns are warranted. In addition, only a small proportion of systemically administered 
drugs reach their intended target. Selective delivery of the drug to the target tissue and use 
of functional protein domains capable of penetrating cells and tissues could alleviate these 
problems in certain circumstances. We will present in this review a novel approach utilizing 
unique molecular fingerprints (“Zip/postal codes”) in the vasculature of regenerating tissues 
that allows target organ-specific delivery of systemically administered therapeutic molecules 
by affinity-based physical targeting (using peptides or antibodies as an “address tag”) to 
injured tissues undergoing repair. The desired outcome of targeted therapies is increased 
local accumulation and lower systemic concentration of the therapeutic payload. We believe 
that the physical targeting of systemically administered therapeutic molecules could be 
rapidly adapted in the field of regenerative medicine. 
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1. Local vs. Systemic Drug Delivery in Regenerative Medicine 
Adult tissues respond to injury differently. Some tissues, such as the bone, repair injuries with 
tissue that is identical to the original tissue. However, most tissues respond by undergoing a repair 
process that only partially restores the original tissue with the rest replaced by non-functioning, 
fibrotic scar tissue [1,2]. 
Numerous growth factors and other agents that could potentially enhance tissue regeneration have 
been identified, but their therapeutic application has been rather limited in clinical medicine [1,3,4]. 
There are several reasons for their limited use: it is difficult to maintain bioactivity of locally applied 
therapeutic agents in regenerating tissue because of lack of retention of the agent, poor tissue penetration, 
and instability of protein therapeutics in the protease-rich environment of the injured tissue [4,5]. 
Moreover, most injuries are not accessible with topical application of therapeutic molecules and multiple 
sites (tissues) of injury further limit the usefulness of local treatment. 
Strikingly, all current efforts aimed at enhancing tissue repair with biologic drugs have been based 
on local application of therapeutic molecules to the injured site [5,6]. Although human diseases are 
treated with systemically administered drugs in general, systemic administration of growth factors has 
been ruled out due to concerns about their systemic use and potential safety. These concerns are 
warranted because the major problems in systemic drug therapy are that only a small proportion of 
administered drug reaches its intended target site(s). In addition, large molecules such as antibodies are 
poor at penetrating tissues and do not always reach the actual target cells [7–10]. Selective delivery of 
the drug to the target tissue and use of functional protein domains, such as cell penetrating peptides, 
capable of penetrating cells and tissues could alleviate some of these problems [10–13]. 
2. Vascular Heterogeneity—“Zip Codes” in Vasculature 
Our increased understanding of the structure of blood vessels on the molecular level has revealed a 
practical possibility for organ-specific therapeutic treatment of various human diseases with systemically 
administered drugs [9,14]. Recent research has shown that each organ has unique molecular structures 
in its blood vessels (“vascular ZIP codes”) [9,14–17] (Figure 1). Each organ confers endothelial cells 
(ECs) in it with their “organotypic”, i.e., unique tissue-specific, features [9,14,15,18]. Clusters of 
transcription factors, angiocrine growth factors, adhesion molecules and chemokines are expressed in 
unique combinations by the ECs of each organ and the blood vessels in each organ can be defined [15]. 
Furthermore, various diseases display disease-specific signatures on the vasculature of the diseased 
tissue [19]. This is especially evident for diseases such as different cancers, or tissue injury, which 
induce new blood vessels by angiogenesis [11]. The angiogenic blood vessels, in turn, are structurally 
distinct from the pre-existing blood vessels in the body [11,20]; a fact also highlighted by different 
types of stem cells being recruited to take part in the process [21]. 
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Figure 1. Target-specific drug therapies in tissue regeneration. Molecular fingerprints 
(“Zip/postal codes”) in the angiogenic vasculature of the regenerating tissues allow target 
organ-specific delivery of the systemically administered therapeutic molecules by  
affinity-based physical targeting (using peptides or antibodies as an “address tag”) to 
injured tissues undergoing repair. The desired outcome of the targeted therapies is similar 
to topical application: increased local accumulation and lower systemic concentration of 
the therapeutic payload. 
The disease and organ-specific molecular “Zip codes” in blood vessels can be utilized for target 
organ-specific delivery of therapeutic molecules by affinity ligands [9,11,14,19]. Affinity-based 
physical targeting (synaphic, pathotrophic, or active targeting) makes use of these vascular ZIP codes, 
i.e., molecular markers that are specifically expressed at the target, and not elsewhere in the body,  
to accomplish selective targeting of systemically administered drugs to the target organ [11]. The desired 
outcome of the synaphic targeting is increased local accumulation and lower systemic concentration of 
the therapeutic payload [11]. 
3. In Vivo Phage Display 
Vascular “ZIP codes” can be easily probed by in vivo phage display, a method first reported by  
Erkki Ruoslahti’s group in 1996 [14]. In vivo phage display allows unbiased exploration of vascular 
diversity by random peptide libraries expressed in bacteriophage [22] (Figure 2). Phage display is a 
powerful method for peptide library screening that provides a physical linkage between peptides  
(i.e., the phenotype), which are displayed on the surface of a bacteriophage particle, and the encoding 
DNA (genotype) [22,23]. 
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Figure 2. Schematic presentation of the principle of in vivo phage display. (A) A cyclic 
CX7C-peptide library is cloned onto the C-terminus of phage coat protein and 415 copies 
expressed per T7 phage via Select 415-1b; and (B) the phage library is injected into the 
circulation. As the homing peptides on the phage bind to endothelium in the tissues, there is 
an enrichment of phage that binds to the endothelium of the target tissue. Target tissue is 
homogenized, cell suspensions prepared, and the bound phage rescued and amplified by 
adding E. coli. The amplified phage pool recovered from the target tissue is re-injected into 
mice at a similar disease stage, and the screening cycle repeated several times to ensure 
phage clones that specifically bind (i.e., home) towards target are recovered. A set of phage 
clones is collected from the homing phage population that shows enrichment towards the 
target tissue. The peptide-encoding DNA inserts are amplified by PCR, and the PCR 
products sequenced. Modified from Ruoslahti [19]. 
Bacteriophage can be genetically modified to incorporate random protein sequences as fusions with 
the coat proteins at a diversity of billions of variants per library, close to the total number of possible 
permutations of a random amino acid sequence [22]. The outcome of generating a random phage library 
is a pool of billions of bacteriophages all identical to each other except for the protein motif expressed 
at the end of its coat protein. For in vivo selection, a library of phage displaying random peptides is 
injected systemically into the animals, followed by removal of target organ, amplification of the 
bound phage from the target organ, and subjecting the amplified pool to another round of selection 
in new animals [22]. In vivo peptide phage screening combines subtractive elements (removal of phage 
displaying pan-specific peptides by all other organs of the body except the given target organ) with 
positive selection at the target tissue [22]. In vivo phage display offers a unique opportunity to screen 
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for potentially billions of protein-based drug candidates simultaneously in an in vivo setting [22]. 
Combination of in vivo phage display and bacterial 2-hybridization allows simultaneous identification 
of ligand-receptor pairs for target organ-specific targeting [24]. 
So far in vivo phage display has been used for several purposes in the field of regenerative medicine: 
to identify peptides capable of homing to the angiogenic blood vessels forming at injured tissues [20] 
and for the identification and illumination of neural structures during surgery [25]. 
4. Angiogenesis—An Opportunity for Vascular Targeting in Regenerative Medicine 
Angiogenesis is a vital requirement for wound healing because the formation of new blood vessels 
allows a variety of mediators, nutrients, and oxygen to reach the healing tissue [1–3,26]. Angiogenesis 
is driven by tissue hypoxia, and inflammation, as both surviving cells and the inflammatory cells  
that have invaded the injured area secrete a large number of angiogenic growth factors [1,3,26,27]. 
During regeneration of injured tissue, angiogenic capillary sprouts invade the fibrin/fibronectin-rich  
clot and within a few days organize into a thick microvascular network throughout the granulation  
tissue [1–3,26,28]. The name, granulation tissue, actually derives from the granular appearance of 
abundant, newly formed blood vessels. As these newly formed blood vessels essentially fill up the 
granulation tissue forming at the site of injury and they differ in molecular structure from  
pre-existing vasculature, they provide an opportunity for vascular targeting of systemically administered 
drugs for purposes of enhancing the tissue regeneration process [20,29,30]. 
5. CRK and CAR Vascular Homing Peptides for Regenerative Medicine 
We have reasoned that it could be possible to deliver systemically administered drugs into 
regenerating tissues in a target organ-specific fashion independent of the location of the injury in the 
body [20]. For that goal, we have probed injured tissues during angiogenesis with in vivo phage display 
to identify protein motifs capable of homing to the injured tissue after systemic administration [20].  
We have identified two peptides that selectively target injured tissues: CARSKNKDC (CAR) and 
CRKDKC (CRK) [20]. CAR is homologous to heparin-binding sites in various proteins and shows the 
highest homology with the main heparin-binding site of the known angiogenic growth factor, bone 
morphogenetic protein 4 (BMP4). In line with that heparin binding site, CAR peptide binds to cell 
surface heparan sulfate proteoglycans (HSPGs) and utilizes HSPGs for efficient cell and tissue 
penetration [20], whereas the CRK peptide is not capable of cell and tissue penetration [20,31]. CRK 
peptide, in turn, has structural similarity to segments in thrombospondin type 1 and 3 repeats identified 
in a large number of proteins. These two vascular homing peptides have a distinct difference in their 
targeting ability; CAR peptide shows a preference for early stages of tissue regeneration, whereas CRK 
favors injured tissues at later stages of healing [20]. 
6. Conjugated Delivery 
Conventional tissue-specific delivery has called for conjugation of a targeting element to the 
therapeutic molecule to obtain a targeted therapeutic molecule (Figure 3). The conjugation can be either 
done by chemical conjugation of the two functional domains or by expressing them together as a 
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recombinant fusion protein. Prime examples of such recombinant fusion proteins include interleukin-10 
(IL-10) fused together with the antibody scFv F8 (F8-IL10, i.e., Dekavil) that recognizes a domain of 
fibronectin expressed exclusively on inflammatory neovasculature [32–35]. This molecule is in clinical 
trials to treat arthritis [32–35]. Other examples include Angiopep, a peptide used to target nanoparticles 
loaded with therapeutic molecules to brains in e.g., Parkinson’s disease [13] and the tumor homing  
NRG-peptide fused together with tumor necrosis factor α (TNFα) to induce anti-tumor and toxic 
reactions towards tumor cells [36,37]. 
The half-life of the most common targeting element, peptides, is usually short in circulation and their 
binding affinity for their respective receptor relatively low. Both of these features can be substantially 
improved by fusing the peptides to become part of a larger recombinant protein or by coating cells or 
nanoparticles with multiple copies of the peptide [11,38]. For example, we have obtained preliminary 
evidence that incorporation of CAR peptide to therapeutic proteins enhances CAR peptide’s binding 
efficacy to its receptors to a nanomolar-level, and more so if the recombinant fusion protein is 
multimerized (expressed as a dimer). One-to-one peptide-payload conjugates can still be quite effective 
in targeting and avoiding side-effects in healthy tissues despite the large size difference between the 
peptide and the therapeutic domain, particularly when the peptide is used to augment an inherent affinity 
of the payload to the target [36,37,39]. A prime example of such complementary targeting is TNFα 
targeted to tumors with the NRG tumor-homing peptide; such a conjugate is now in phase 3 clinical 
trials [36,37], and CAR-peptide targeted decorin [39]. Decorin has been reported to home to angiogenic 
vasculature through a core protein-dependent interaction [40], but despite its inherent homing ability, 
the CAR peptide was able to enhance the accumulation of the fusion protein to sites of angiogenesis 
approximately 500% over native decorin [39]. An illustrative example of using multiple copies of 
short targeting peptides is by “painting” the intended therapeutic domain with multiple copies of the 
peptide. Such an approach is utilized when targeting stem cells to desired loci by “painting” the stem 
cells with multiple copies of the homing peptide [38,41]. Both CAR and CRK peptides have been  
used successfully to target mesenchymal stem cells to infarcted myocardium after “painting” the cells 
with multiple copies of the peptide [38,41]. The benefit of using homing peptides that are also cell 
penetrating peptides (CPPs) is that such a peptide greatly increases the transport of the drug to the 
extravascular tissue [10,20,39] (Figure 3). 
Even more remarkable is the fact that the targeting domain can enhance the activity of the therapeutic 
molecule [39]. We have found that a vascular homing peptide for a tissue or lesion often also binds to 
the corresponding parenchymal cells [11], and this is the case with CAR, which also recognizes the 
granulation tissue in wounds [39]. This localization of the peptide receptor drives the translocation of 
the blood vessel-bound peptide into the injured tissue, where the therapeutic payload can exert its 
functions more potently as it is anchored on the target cells. We were able to show that the anchorage to 
target cells provided by CAR peptide’s fusion to decorin, enhanced decorin’s biological potency to 
neutralize transforming growth factor-β (TGF-β) [39]. Later, Hubbell et al. generated “super” growth 
factors, i.e., more potent growth factors than native ones, simply by fusing them with the heparin-binding 
domain of BMP2 (analogous to the CAR peptide, which is a close homologue to the heparin binding 
domain of BMP4) [6]. 
Int. J. Mol. Sci. 2015, 16 23562 
 
 
 
Figure 3. Systemically administered, targeted therapies: (A) The drugs are conjugated 
physically to the targeting device in conventional drug targeting. For protein-based 
therapeutics, targeting domain and therapeutic molecule are fused together as a recombinant 
protein with enhanced activity and tissue-specificity in conjugated delivery; (B,C) Bystander 
effect: Compounds co-injected with tissue-penetrating homing peptides are transported across 
the vessel wall and through tissue together with the peptides [12,42–45]. No physical conjugation 
is needed between the targeting peptide and drug; the cell penetrating homing peptide 
“sweeps” co-injected drugs to its target (homing) tissue in tissue-specific fashion [12,42,45]. 
One of the benefits of using short peptides as targeting elements, is that the peptides are unlikely to 
be immunogenic in themselves because they are simply too small. For example, they are a fraction of 
the size of the highly variable complementary determining regions (CDRs) of therapeutic antibodies, 
which generally have an excellent drug safety and low immune reaction record [10]. Furthermore, when 
analyzing the homology of homing peptides (by BLAST), these short and stable cyclic peptides typically 
show high levels of homology to parts of native proteins found across a range of species indicating that 
the functional domain in the homing peptide is conserved between species (as is the case for both CRK 
and CAR, for example) [20]. This would predict high tolerance of the peptide by the immune system. 
These pharmacological properties highlight the importance of advancing multi-functional, 
systemically administered, target-seeking recombinant fusion proteins. However, unless the target of a 
homing peptide is known to be unimportant for function of the immune system, cell proliferation, 
angiogenesis, etc., one cannot rule out the possibility of adverse effects caused by high doses of a homing 
peptide binding to its target receptor. Thus, it is necessary to elucidate the target and mechanism of 
homing peptides, and to investigate their safety. 
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7. Bystander Effect 
The latest results have revealed a tissue-penetrating transport pathway for certain targeting peptides 
that can be used to enhance drug targeting without requiring any conjugation between the therapeutic 
and targeting domains [43–45] (Figure 3). The essential features of the system called the “bystander 
effect” were first elucidated using a new RGD (an integrin binding sequence) peptide, termed iRGD 
because it internalizes into target cells [43,45] (Figures 3 and 4). Like conventional RGD peptides [46], 
iRGD accumulates at tumor vasculature as a result of integrin binding; but it is then cleaved by a protease 
to unmask a second binding motif, a so-called CendR motif (consensus: R/KXXR/K) [43–45]. The 
CendR motif binds to neuropilin-1, which activates a transport tissue-penetration and cell internalization 
pathway [43–45]. Remarkably, the CendR pathway is a bulk transport system. Once activated, it will 
sweep along any molecule or nanoparticle (“Bystander effect”) that is present in the environment  
(Figure 3). Thus, it is not necessary to couple iRGD to the compound to be targeted; the therapeutic 
molecule can be simply co-injected with the vascular homing peptide capable of inducing the bystander 
effect, which will sweep the molecule into the target organ [42–45] (Figure 3). 
 
Figure 4. CAR peptide homes to inflammatory vasculature in pulmonary arterial hypertension 
(PAH) and induced target-tissue selective vasodilation in PAH. (A) PAH was induced in rats 
by a single subcutaneous injection of SU5416 and three week exposure to hypoxia (10% O2) 
followed by six weeks of normoxia [42,47]. CAR peptide accumulates in remodeled pulmonary 
arteries (A/C: occlusive neointimal formation) [42,47]. Little signal was detected in  
lung lesions of the PAH rats administered with CAR mutant peptide; (B) CAR peptide was 
given orally (p.o.) at the same time with Imatinib (Gleevec). CAR peptide makes drugs  
tissue-selective in PAH, i.e., the drugs are substantially more potent in the pulmonary 
vasculature (RVSP) where the PAH takes place, whereas the blood pressure lowering effect 
induced by CAR co-administration is unchanged on the systemic side of the circulation 
(SAP), * p < 0.05; and (C) Schematic presentation of targeted delivery by the bystander 
effect induced by vascular homing peptide CAR. 
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We have recently noted a bystander effect for a vascular homing and cell penetrating peptide that 
does not contain the CendR-motif [42] (Figures 3 and 4). We have shown that the CAR peptide, that 
does not have a CendR-sequence in it [42], is a very potent inducer of a bystander effect in pulmonary 
hypertension (PAH) [42] (Figure 4). Namely, CAR peptide homes to the inflammatory vasculature in 
a rat model of PAH and penetrates to inflammatory lung parenchyme [42,47] (Figure 4). We have 
shown that it can convert any vasodilator drug to become a target organ-specific vasodilator in that 
model of PAH; when a low dose of vasodilator is given together with CAR peptide, the drug 
accumulates in the diseased lungs and lowers the hypertension selectively only in the pulmonary 
circulation and leaves the systemic circulation unaffected for target organ-specific vasodilation [42] 
(Figure 4). It remains to be determined whether CAR- or CendR-peptides induce a bystander effect 
that could be used for therapeutic advantage in regenerative medicine. 
8. CAR-Decorin—Target Organ-Specific Systemically Administered Anti-Fibrotic Molecule 
Decorin (DCN) is the best characterized member of the extracellular small leucine-rich proteoglycan 
family. It is present in a variety of connective tissues, typically in association with or “decorating” 
collagen fibrils, and has substantial interest to clinical medicine owing to its well established anti-fibrotic 
and pro-regenerative effects [48–50]. DCN is a natural inhibitor of TGF-β that shuts down the TGF-β 
responses related to injury, cancer growth and inflammation [39,49–53]. In addition to blocking  
TGF-β, DCN also inhibits other important inducers of fibrosis/scarring; myostatin and connective tissue 
growth factor (CTGF/CCN2) [29,50,54–56]. The ability of decorin to prevent scar formation and fibrosis 
and to simultaneously promote tissue regeneration has been demonstrated in a large number of tissue 
injuries and diseases [49–51]. We have recently developed a systemically administered, targeted,  
e.g., inflammation and angiogenesis homing version of DCN core protein [39] (Figure 5). The 
angiogenesis and inflammation specificity of our enhanced DCN core protein is obtained by a fusion to 
the CAR homing peptide that functions as an address tag in the fusion protein and delivers systemically 
administered DCN to angiogenic and inflammatory vasculature [29,39] (Figures 5 and 6). CAR peptide 
can deliver increased amounts of DCN in a tissue-specific manner with a significant therapeutic 
advantage over ordinary DCN core protein in healing skin wounds [29,39] (Figures 5 and 6). Furthermore, 
the fusion of CAR to recombinant DCN enhances its neutralization effect on TGF-β [39]. The molecular 
explanation for the enhanced biological activity of CAR-DCN is that the CAR peptide binds to HSPGs 
on the target cells. TGF-β1, and TGF-β2 in turn, also bind heparan sulfate and HSPG binding increases 
their biological activity [29,39] (Figure 5). Thus, CAR mediated binding of CAR–DCN to HSPGs 
may enhance the neutralizing effect of the fusion protein by bringing it into the proximity of the  
HSPG-binding TGF-βs [29,39] (Figure 5). 
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Figure 5. Schematic representation of the mechanism of action of the systemically 
administered, target organ-specific anti-fibrotic molecule, CAR-decorin. CAR-decorin (1) 
is a systemically administered, target-seeking, multi-functional biotherapeutic that inhibits 
scar formation. The molecule can be targeted to injury taking place at any organ of the body 
(2, 3) (or multiple organs simultaneously). The CAR homing peptide targets angiogenic 
vasculature, which forms at the site of the injury (4, 5). The peptide (and any payload 
attached to it; blue stars) then extravasates into surrounding tissue (6), where it binds to its 
receptor(s) on the cell surface of the scar producing fibroblasts (7). CAR binding to heparan 
sulfate proteoglycans (HSPGs) provides docking sites in the proximity of the main  
scar-inducing growth factors TGF-β1 and TGF-β2 (8) facilitating the neutralization of these 
growth factors by the therapeutic part of the molecule, decorin (8). This mechanism results 
in therapeutic response (9) seen as reduced scar formation in the skin [39]. Picture by Helena 
Schmidt; reproduced after modification with permission from [57], Copyright 2011 Finnish 
Medical Journal Duodecim. 
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Figure 6. Targeted delivery of systemically administered therapeutics to the regenerating 
tissues. (A) 2-Photon fluorescence microscopy of vascular homing peptide accumulation to 
wound vasculature illustrates the specificity of the vascular targeting [30]. 2-Photon 
fluorescence microscope allows 3-D imaging of whole tissues [30]; and (B) Mice with full 
thickness skin wounds received an i.v. injection of His-tagged fusion proteins. The location 
of decorin was determined with an anti–His-tag antibody. The wounds of mice injected with 
non-targeted decorin (DCN) or mutant CAR peptide coupled decorin (mCAR-DCN) were 
weakly positive, whereas strong wound staining was observed in CAR-DCN injected  
mice [39]. The accumulation of CAR fused to human serum albumin (CAR-HSA) in the 
wounds confirmed the ability of the CAR peptide to enhance targeting to the wounds in 
fusion proteins other than DCN [39]. No staining was observed in normal skeletal muscle 
underlying the skin wounds of mice treated with any of the decorins. The staining was 
quantified by digital histology. The statistical significance was examined with ANOVA;  
** p ≤ 0.01, *** p < 0.001 [39]. 
9. Future Perspectives 
In diseases affecting lungs, the CAR peptide has also recently been shown to target inflammatory 
vasculature (Figure 4) [42,47,57–61] and to deliver different pharmaceutical agents in a target  
organ-specific fashion to diseased lungs (Figure 4) [42]. Furthermore, both CAR and CRK peptides  
have been used to target mesenchymal stem cells to infarcted myocardium [38]. Thus, CAR-targeted 
therapeutic molecules could also be useful in the treatment of chronic, inflammatory diseases 
(outside of healing wounds), or in diseases where there is angiogenesis or inflammation affecting 
the local vasculature. 
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